GSK
-
Data at the end of a long-term study shows Shingrix continues to provide high protection against shingles in adults aged 50 and over for more than a decade
GSK plc (LSE/NYSE: GSK) has announced positive data from the ZOSTER-049 long-term follow-up phase III trial which followed participants for…
Read More » -
GSK launches once daily, single inhaler-triple therapy for COPD patients for the first time in India
Bangalore GlaxoSmithKline Pharmaceuticals Limited launched Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol), the first single-inhaler triple therapy (SITT) in India for Chronic Obstructive Pulmonary Disease (COPD) patients in a once-daily regime. The launch follows the product’s approval by the Drugs Controller…
Read More » -
Veeva Teams With Life Sciences to Offer Industrywide Source for Key Contacts, Information, and Services From Across Companies and Brands
Sydney, Australia: MyVeeva for Doctors app makes it easy for HCPs to access the people and resources they need to…
Read More »